Breast CancerPhase 3NCT00814125
ATAC - Endometrial Sub-Protocol
A Phase 3 study testing Anastrozole (Arimidex) and Tamoxifen (Nolvadex) in people with Breast Cancer, run by AstraZeneca.
Trial summary
To compare the difference between the ARIMIDEX group and the tamoxifen group in the incidence of abnormal endometrial histological findings arising after treatment has commenced. Read more about this study
- Who is it for?
- Ages 45 years and older, women only
- Conditions the study is for
- Breast Cancer
- What is being tested?
- Anastrozole (Arimidex) and Tamoxifen (Nolvadex)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 285 participants
- Where
- No sites listed yet
- Study dates
- Jun 1997to Dec 2005
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients eligible for entry into the main ATAC trial (1033IL/0029)
- Not received any previous tamoxifen, for whatever reason
- Not undergone a hysterectomy and do not have a hysterectomy planned within the next 6 years
- No previous endometrial ablation
Who cannot join
- Excluded from entry into the main ATAC trial (1033IL/0029). As detailed in Section 4.4 of the main ATAC trial (1033IL/0029)
About this study
Official title: A Randomised, Double Blind Trial to Assess the Incidence of Endometrial Changes With Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, When Used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women
To compare the difference between the ARIMIDEX group and the tamoxifen group in the incidence of abnormal endometrial histological findings arising after treatment has commenced.
- Conditions
- Breast Cancer
- Being tested
- Anastrozole (Arimidex), Tamoxifen (Nolvadex), Nolvadex placebo, Arimidex placebo
- Keywords
- Endometrial, Endometrial histological findings
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Anastrozole (Arimidex)Drug
Also called Arimidex
1mg, orally, once daily
Tamoxifen (Nolvadex)Drug
Also called Nolvadex
20mg, orally, once daily
Nolvadex placeboDrug
Arimidex placeboDrug
| Study group | Role | What they receive |
|---|---|---|
| 1 | Active comparator | Arimidex 1mg + Nolvadex placebo Receives: Drug: Anastrozole (Arimidex); Drug: Nolvadex placebo |
| 2 | Active comparator | Arimidex placebo + Nolvadex 20mg Receives: Drug: Tamoxifen (Nolvadex); Drug: Arimidex placebo |
| 3 | Active comparator | Arimidex 1mg + Nolvadex 20mg Receives: Drug: Anastrozole (Arimidex); Drug: Tamoxifen (Nolvadex) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Withdrawl
Death
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Dec 2008 (estimated)
- Study startJun 1997
- Study completionDec 2005
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 285 participants (actual)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00814125
- Sponsor's protocol ID
- 1033IC/0029
- Other IDs
- D5392C06736
- Status last verified
- Apr 2009
- First submitted
- 3 Nov 2008
- Last updated
- 1 May 2009
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 1 May 2009. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomised, Double Blind Trial to Assess the Incidence of Endometrial Changes With Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, When Used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women
- ClinicalTrials.gov ID
- NCT00814125
- Acronym / sponsor ID
- 1033IC/0029
- Conditions
- Breast Cancer
- Keywords
- Endometrial, Endometrial histological findings
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 285 participants (actual)
- Lead sponsor
- AstraZenecaIndustry (pharma, biotech, devices)
- Study start
- Jun 1997
- Study completion
- Dec 2005 (actual)
- First posted
- 24 Dec 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To compare the difference between the ARIMIDEX group and the tamoxifen group in the incidence of abnormal endometrial histological findings arising after treatment has commenced.
Study design
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| 1 | Active comparator | Drug: Anastrozole (Arimidex), Drug: Nolvadex placeboArimidex 1mg + Nolvadex placebo |
| 2 | Active comparator | Drug: Tamoxifen (Nolvadex), Drug: Arimidex placeboArimidex placebo + Nolvadex 20mg |
| 3 | Active comparator | Drug: Anastrozole (Arimidex), Drug: Tamoxifen (Nolvadex)Arimidex 1mg + Nolvadex 20mg |
Who may qualify
- Ages
- 45 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Patients eligible for entry into the main ATAC trial (1033IL/0029)
- Not received any previous tamoxifen, for whatever reason
- Not undergone a hysterectomy and do not have a hysterectomy planned within the next 6 years
- No previous endometrial ablation
Key exclusion criteria (1 listed)
- Excluded from entry into the main ATAC trial (1033IL/0029). As detailed in Section 4.4 of the main ATAC trial (1033IL/0029)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Anastrozole (Arimidex)Also: Arimidex1mg, orally, once daily | Drug | 1, 3 |
| Tamoxifen (Nolvadex)Also: Nolvadex20mg, orally, once daily | Drug | 2, 3 |
| Nolvadex placebo | Drug | 1 |
| Arimidex placebo | Drug | 2 |
Primary outcome
Withdrawl
Death
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 May 2009.
Related trials for Breast Cancer
Active, not recruitingPhase 2
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7
RecruitingPhase 1/2
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Breast Cancer
Not yet recruiting
Podcast-Based Psychosocial Support for Women Newly Diagnosed With Breast Cancer
Breast Cancer
Recruiting
A Study of Skipping Radiation Therapy in People With Breast Cancer
HER2-positive Breast Cancer, Breast Cancer
Active, not recruiting
Dance Study for Post-surgical Pain in Breast Cancer Survivors
Breast Cancer, Survivorship
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Anastrozole (Arimidex) and Tamoxifen (Nolvadex) in people with Breast Cancer, run by AstraZeneca.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 May 2009. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Withdrawl. The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 May 2009.